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Kidney cancer in the Swedish Family Cancer Database: Famil- nosed with kidney cancer has improved over time, with
ial risks and second primary malignancies. five-year relative survival rate increasing from 30 to 40%
Background: Familial risks in kidney cancer and association in the 1960s to 50 to 60% in the 1990s [3]. Renal cellwith second primary malignancies were studied using the na-
cancer (renal parenchymal cancer) represents about 80tionwide Swedish Family Cancer Database.
to 85% of all adult kidney neoplasms. In Sweden, cancerMethods: Cancer data were retrieved from the Swedish Can-
cer Registry from years 1961 to 1998 and included 23,137 cases of the renal parenchyma accounted for 82%, renal pelvis
of kidney cancer. Standardized incidence ratios (SIRs) were cancer for 9% and cancer at unspecified sub-sites for
used to measure the cancer risks. 9% of the total number in 1997 [4].Results: Seventy-one families were identified where both a
Kidney cancer occurs in both sporadic and familialparent and an offspring had kidney cancer, giving a familial risk
forms. Familial kidney cancer is rare because only afor offspring of 1.56 (1.22 to 1.95) and population attributable
proportion of 0.78%. A risk for kidney cancer from an affected few percent of first-degree relatives share this type of
sibling was considerably higher with a SIR of 4.72 (2.28 to neoplasia [5]. Familial cancers can be caused by environ-
9.20), giving an attributable proportion of 0.77%. The discor-
mental factors and habits shared by family membersdant tumor site that was associated with kidney cancer between
or by inherited gene defects. It is often impossible totwo generations was hemangioblastoma of central nervous sys-
tem. Discordant cancer sites that were associated with kidney apportion the environmental and heritable components;
cancer in siblings were ovaries, endocrine glands and pancreas. in twin studies such estimated can be obtained, but for
There was an over threefold increase of second primary malig- kidney cancer even the largest published twin study was
nancies of the urinary bladder, nervous system and endocrine
non-informative because of lack of concordant twin pairsgland in kidney cancer patients. The risks for second primary
[6]. However, for cancers lacking strong identified envi-hemangioblastoma following kidney cancer or familial kidney
cancer was 21.19 (6.69 to 43.83) and 1206 (114 to 3456), respec- ronmental risk factors, such as kidney cancer, familial
tively. risk factors may primarily reflect heritable risks [7, 8].
Conclusions: The high ratio of sibling risk to offspring risk Familial renal cell cancer is manifested as a part of ain kidney cancer may reflect a recessive susceptibility. The high
rare autosomal-dominant cancer syndrome, von Hippel-risk for second primary cancers in the patients without family
Lindau (VHL) disease [1, 9]. VHL is a monogenic dis-history is consistent with a polygenic model and variable degree
of environmental modification. ease caused by alteration in the von Hippel-Lindau
(VHL) gene at chromosome 3p [10]. Affected individuals
are at risk of developing tumors in number of organs,
Malignant tumors of the kidney account for 2 to 3% including the kidneys, central nervous system (hemangi-
of adult cancers worldwide [1, 2]. Kidney cancer occurs oblastoma), eye, inner ear, endocrine glands, and pan-
about twice as often among men as among women, with creas [11]. Renal pelvis cancer is a manifestation in he-
average age at diagnosis of 60 to 65 years [3]. Incidence reditary nonpolyposis colorectal carcinoma (HNPCC)
rates vary more than tenfold between countries, being with about fivefold risk in mutation carriers in mismatch
highest in Scandinavia and other parts of northern Eu- repair genes [12]. In a limited number of non-VHL fami-
rope, and in North America. Survival of patients diag- lies the genetic defects have been characterized to be
inherited translocations, many of which include chromo-
some 3 [13]. Renal cancer also is involved in tuberousKey words: heredity, kidney cancer, hemangioblastoma, VHL, second
cancer, tumor. sclerosis, but most cases represent new mutations; brain
tumors occur in a small number of cases [14]. AnotherReceived for publication July 10, 2001
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fected family members develop multiple papillary tu- between years 1958 and 1960, we used the follow-up
period between 1 January 1961 and 31 December 1998.mors of varying size in both kidneys [15, 16]. Some, but
not all papillary renal cell carcinomas have been shown A four-digit diagnostic code according to the 7th revision
of the International Classification of Diseases (ICD-7)to be caused by activating mutations in the c-MET proto-
oncogene. Some recently characterized renal cancers are was used in combination with histology codes. The fol-
lowing ICD-7 codes were pooled: “upper aerodigestiveBirt-Hogg-Dube syndrome with mainly chromophobe
tumors and familial renal oncocytoma [13]. tract” cancer codes 161 (larynx), and 140–148 (lip,
mouth, pharynx), except for code 142 (salivary glands);Second primary malignancies associated with renal cell
carcinoma include those of urinary bladder, prostate, and “leukemia” codes 204–207 (leukemias), 208 (polycy-
themia vera), and 209 (myelofibrosis). Kidney cancerrectal and lung cancer, as well as non-Hodgkin’s lym-
phoma and melanoma [17–22]. The etiology of second (ICD-7 code 180) was subdivided to cancer of the renal
parenchyma (1800), renal pelvis (1801) and cancer atcancers is most likely multifactorial and may include
effects of radio- and chemotherapy, genetic predisposi- unspecified sub-sites (1809). The main histopathological
types of kidney cancer were adenocarcinoma, papillarytion, environmental exposures such as ultraviolet light,
impaired immunological mechanisms, gender specific type and Wilms tumor with pathological anatomic diag-
nosis (PAD) codes 096, 116 and 886. Hemangioblastomaand hormonal factors and interactions of these factors.
Here we used the nationwide Swedish Family-Cancer was defined as benign tumor of the central nervous sys-
tem (ICD-7 code 193) with PAD code 501 and 511.Database, which comprises 10 million individuals and
more than 1 million cancers, to assess the familial risks Besides hemangioblastoma there are a few other benign
tumors of central nervous system and endocrine glandsin kidney cancer. Familial risks in kidney cancers have
previously been studied among some 20 other cancer included in our Database to which were generally re-
ferred to as “cancer” during our analysis.sites or between different sites using our Database [5,
23, 24]. In this study we investigated the familial relation- The incidence of second cancer was analyzed in all
patients with an initial kidney cancer diagnosed betweenships of kidney cancer in detail and analyzed the site-
specific risk of second primary neoplasm among 23,137 1 January 1961 and 31 December 1998. During this pe-
riod of time 1900 patients developed a second primarypatients diagnosed with a kidney cancer during the years
1961 to 1998. malignancy among 23,137 kidney cancer patients. Cases
of second primary kidney malignancies in the Database
were taken into analysis when the diagnosis date of the
METHODS
first and second malignancy differed by at least one
The Swedish Family Cancer Database month in order to exclude the possibility of two notifica-
tions of the same cancer.The Swedish Family Cancer Database includes all per-
sons born in Sweden after 1931 with their biological
Statistical analysisparents, totaling over 10.2 million individuals [25]. The
Database is organized into 3.1 million families, with par- Standardized incidence ratios (SIRs) were used to
measure the cancer risks for offspring according to occur-ents and offspring. It has been updated in the beginning
of year 2001 to include cancers from the nationwide rence of cancers in their family. Cancer risks in offspring
who had a parent affected with cancer are referred toSwedish Cancer Registry from the years 1958 to 1998.
Of the invasive cancers, over 769,000 were diagnosed as “offspring risk.” Cancer risks in offspring who had a
sibling affected with the cancer are referred to as “siblingamong parents and 166,000 among offspring.
Since 1958, all new cases of cancer in Sweden have risk.” SIRs were calculated as the ratio of observed (O)
to expected (E) number of cases. The expected numbersbeen reported to Swedish Cancer Register. The com-
pleteness of cancer registration in the 1970s has been of cancers were obtained by assuming that these persons
experienced the same cancer incidence as prevailed inestimated to be over 95%, and is now considered to be
close to 100%. This has been achieved by compulsory the corresponding general population in the Database.
Tumor site-, sex-, period- and age-specific rates werereporting from clinicians who diagnose a neoplasm and
the pathologists/cytologists who must report separately applied to the appropriate person-years at risk [26]. For
first primary cancer, person-years at risk were accumu-any diagnosis of malignancy made on pathological and
cytological specimens. lated for each offspring beginning with the date of birth
or January 1, 1961 and ending with the date of diagnosis
Patients of a first primary cancer, date of death, date of emigra-
tion, or December 31, 1998.Offspring were diagnosed for their first primary cancer
at ages 0 to 66 years, while the age of parents at their For each cancer pair, that is, offspring-parent (in calcu-
lating “offspring risk”) and offspring-sibling (in calculat-diagnosis was not limited. Since there is incomplete infor-
mation in the Database about death among cancer cases ing “sibling risk”), we counted cancer cases and person-
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years at risk only once for each offspring regardless of the increased in offspring giving a SIR of 1.56 (range 1.22
to 1.95). Risk was similar for both genders: 1.52 (1.10 tonumber of affected members in the family. Confidence
intervals (95% CI) were calculated assuming that the 2.01) in sons and 1.64 (1.09 to 2.30) in daughters. At a
parental age of diagnosis 66 years (the same age limitnumbers of cancers among offspring follow a Poisson
distribution [26]. In the calculation of 95% CIs for sibling as for offspring), the risk of kidney cancer in offspring
was 1.94 (1.36 to 2.61), while at higher parental age itrisks, the dependence between the affected pairs was
taken into consideration [27]. The population-attribut- was lower with SIR of 1.29 (0.90 to 1.77).
A discordant tumor site that associated with kidneyable proportion of cases with family history of kidney
cancer was estimated as follows: (familial SIR  1)/ cancer between the two generations was hemangioblas-
toma of the central nervous system. The SIRs for heman-familial SIR  proportion of familial cases [28].
Standardized incidence ratios were used to estimate gioblastoma by parental kidney cancer and age at diag-
nosis are shown in Table 3. SIR by parental kidney cancerthe risk for a new primary cancer after kidney cancer.
Person-years at risk were accumulated for each patient was 8.51 (3.06 to 16.69) for offspring diagnosed before
the age of 25 years and 2.52 (1.08 to 4.57) for offspringbeginning with the date of diagnosis of the first primary
cancer and ending with the date of diagnosis of a second diagnosed later. The highest risk for hemangioblastoma
by parental kidney cancer of 17.39 (5.49 to 35.98) wasprimary cancer, date of death, date of emigration, or
December 31, 1998, whichever came first. Family histor- observed for sons of parent with kidney cancer when
diagnosed before age 25.ies SIRs for second cancers were calculated in a similar
way, starting at the follow-up from the diagnosis of the The sibling risk from a kidney cancer proband was
4.72 (2.28 to 9.20) (Table 4). Among 32 sibs with kidneykidney cancer. Family history information was collected
on all first-degree relatives (parents, siblings, and chil- cancer 18 were males, giving a SIR of 4.34 (1.81 to 9.29)
for males and 5.34 (2.06 to 12.02) for females. Discordantdren). The follow-up time was divided into three periods
(1 year; 1 to 10 years; 11 to 37 years) allowing the sites that associated with kidney cancer among sibs were
ovaries with a SIR of 1.77 (1.03 to 2.71) and non-thyroidassessment of the effect of follow-up time.
endocrine glands that increased risk for kidney cancer
in males with a SIR 2.37 (1.22 to 3.90). In addition, a
RESULTS SIR of 3.53 (1.11 to 7.30) was observed when young
The annual incidence rates for male and female kidney age of onset (50 years) was combined with pancreatic
cancer in Sweden for the period 1961 to 1998 (standard- cancer of the sibling. Among the 32 affected siblings
ized according to the European standard population) are with kidney cancer only one had an affected parent with
shown in Figure 1A. The male incidence was about 1.7 kidney cancer and 15 had a parent with other cancer
times higher than the female incidence throughout the type; 4 cases of parental colon cancer resulted in SIR of
analyzed period. In both genders the incidence rates 17.57 (3.23 to 55.15), 4 cases of parental urinary bladder
slightly decreased after 1985 and reached 6.80 for women cancer in SIR of 32.35 (5.95 to 101.58) and 2 cases of
and 11.30 for men per 100,000 person-years in year 1998. parental melanoma in SIR of 42.87 (2.86 to 173.77).
The age dependence of the incidence rates of kidney Using the familial SIRs and the proportion of familial
cancer is shown in Figure 1B. After the age of 50 years cases of kidney cancer, we calculated the population-
the incidence of kidney cancer increased steadily both attributable proportions for family history. The attribut-
in males and females. able proportion by parental kidney cancer (using familial
Table 1 reports the characteristics of kidney cancer SIR data from Table 2) was 0.78% [that is, (1.56  1)/
malignancies in the Family-Cancer Database by sub-sites 1.56 (71/3268); the last term is the number of offspring
and histological type. There were 23,137 cases of kidney with an affected parent, divided by the number of all
cancer during the years 1961 through 1998. Cancer of offspring with kidney cancer]. The attributable propor-
the renal parenchyma accounted for 83.7%, renal pelvis tion by sibling’s kidney cancer was 0.77% (using familial
cancer for 8.8%, and cancer at unspecified sub-sites for SIR values from Table 4).
7.5%. The most common histological type was adenocar- Table 5 reports on the risk of second primary cancers
cinoma, which accounted for 81% of all kidney cancers. following kidney cancer by follow-up time. Since no ap-
Among 23,137 kidney cancer cases in Database, 3268 parent sex-specific differences were noted (except for
cases were observed in the offspring (1969 in men and second primary cancer of urinary bladder) when the
1299 in women) and 19,869 cases were observed in par- analysis was carried out separately for males and females,
ents (11,824 in men and 8045 in women). the results in Table 5 are presented for combined gen-
The risks of kidney cancer in offspring in association ders. For patients with kidney cancer, a significantly ele-
with any cancer in parent are shown in Table 2. There vated overall SIR for second primary cancer was found:
were 71 parent-offspring pairs concordant for kidney colon (1.39), pancreas (1.81), lung (1.36), breast (1.25),
prostate (1.70), kidney (2.00), urinary bladder (4.56),cancer in the Database. The risk of kidney cancer was
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Fig. 1. Incidence of kidney cancer in males
and females according to (A) age as standard-
ized according to the European population
standard, and (B) by five-year age ranges.
Symbols are: (, ) males; (, ) females.
nervous system (4.12), endocrine glands (5.25), Non- DISCUSSION
Hodgkin lymphoma (1.86), and leukemia (2.45). The Few analytical epidemiological studies have presented
highest risk of second cancer was found within less than quantitative risk estimates for family history of kidney
one year of follow-up, probably due to intensive medical cancer [23, 29]. While some authors found a 60% in-
surveillance. In the 1 to 10 year interval a higher SIR creased risk for kidney cancer when a first-degree rela-
was observed as compared to 11 to 37 year interval for tive was affected with the disease [29], no association
cancers at urinary bladder (4.01) and nervous system was found in a smaller study [30]. In a study on the Utah
(2.80). The highest risk of second primary tumor was population, analysis of familial relationships in kidney
found for hemangioblastoma of central nervous system cancer (among many other cancer sites) has shown famil-
with a SIR of 18.99 in the 1 to 10 year interval and of ial risk of 1.53 [31]. In agreement with that analysis, we
21.19 overall. In addition, the risk of hemangioblastoma found that the risk to offspring when their parent had
cancer was 1.56 (1.22 to 1.95). Interestingly, sibling riskfollowing familial kidney cancer was 1206 (114 to 3456).
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Table 1. Kidney cancer by sub-sites and histopathological distribution
Cancer sub-sites
Renal parenchyma Renal pelvis Unspecified All
Histopathological type Cases % Cases % Cases % Cases %
Males
Adenocarcinoma 10778 78.14 20 0.15 345 2.50 11143 80.79
Papillary type 17 0.12 1090 7.90 3 0.02 1110 8.05
Wilms tumor 230 1.67 0 0.00 5 0.04 235 1.70
Others 475 3.44 182 1.33 648 4.70 1305 9.46
All 11500 83.37 1292 9.38 1001 7.26 13793 100.00
Females
Adenocarcinoma 7276 77.87 10 0.11 237 2.54 7523 80.51
Papillary type 7 0.07 615 6.58 1 0.01 623 6.67
Wilms tumor 253 2.71 0 0.00 3 0.03 256 2.74
Others 326 3.49 124 1.33 492 5.26 942 10.08
All 7862 84.14 749 8.02 733 7.84 9344 100
The % denotes the percentage of all kidney cancers.
Table 2. SIR for kidney cancer in offspring by parental cancer
Sons Daughters Both
Cancer site in parents O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 20 1.05 0.64–1.57 10 0.84 0.40–1.43 30 0.97 0.65–1.35
Stomach 41 0.85 0.61–1.12 21 0.72 0.45–1.06 62 0.80 0.61–1.01
Colon 62 0.97 0.75–1.23 34 0.88 0.61–1.20 96 0.94 0.76–1.14
Rectum 34 0.93 0.65–1.27 24 1.09 0.70–1.57 58 0.99 0.75–1.27
Liver 26 0.90 0.59–1.28 18 1.04 0.62–1.58 44 0.95 0.69–1.26
Pancreas 22 0.79 0.50–1.16 17 1.00 0.58–1.53 39 0.87 0.62–1.16
Lung 61 1.08 0.83–1.37 37 1.07 0.75–1.44 98 1.08 0.88–1.30
Breast 96 1.08 0.88–1.31 45 0.82 0.60–1.08 141 0.98 0.83–1.15
Cervix 20 1.07 0.65–1.60 6 0.50 0.18–0.99 26 0.85 0.56–1.21
Endometrium 21 0.86 0.53–1.27 17 1.16 0.67–1.78 38 0.97 0.69–1.31
Ovary 28 1.36 0.90–1.90 14 1.13 0.62–1.80 42 1.27 0.92–1.68
Prostrate 121 1.08 0.90–1.28 80 1.19 0.94–1.46 201 1.12 0.97–1.28
Kidney 43 1.52a 1.10–2.01a 28 1.64a 1.09–2.30a 71 1.56a 1.22–1.95a
Renal parenchyma 39 1.65a 1.18–2.21a 23 1.62a 1.02–2.35a 62 1.64a 1.26–2.07a
Renal pelvis 1 0.40 0.00–1.58 5 3.32a 1.05–6.87a 6 1.51 0.54–2.95
Unspecified 3 1.33 0.25–3.26 0 3 0.82 0.15–2.00
Urinary bladder 35 0.92 0.64–1.26 20 0.86 0.53–1.28 55 0.90 0.68–1.16
Melanoma 17 1.07 0.62–1.64 8 0.78 0.33–1.41 25 0.96 0.62–1.37
Skin 21 0.76 0.47–1.12 11 0.65 0.32–1.09 32 0.72 0.49–0.99
Nervous system 14 0.65 0.35–1.03 18 1.34 0.80–2.04 32 0.91 0.63–1.26
Endocrine glands 15 1.18 0.66–1.85 9 1.14 0.51–2.00 24 1.16 0.74–1.68
Non-Hodgkin 24 1.11 0.71–1.60 6 0.45 0.16–0.88 30 0.86 0.58–1.19
Leukemia 20 0.86 0.53–1.28 16 1.12 0.64–1.74 36 0.96 0.67–1.30
Any cancer 726 1.00 0.93–1.08 440 0.99 0.90–1.09 1166 1.00 0.94–1.06
Abbreviations are: O, observed cases; CI, confidence interval; SIR, standardized incidence ratio.
a 95% CI does not include 1.00
Table 3. SIR for hemangioblastoma of central nervous system in offspring by parental kidney cancer
Age 25 Age 25 All ages
Offspring O SIR 95% CI O SIR 95% CI O SIR 95% CI
Sons 5 17.39a 5.49–35.98a 4 2.44 0.63–5.42 9 4.67a 2.12–8.22a
Daughters 1 2.40 0.00–9.40 4 2.61 0.68–5.79 5 2.56 0.81–5.30
Both 6 8.51a 3.06–16.69a 8 2.52a 1.08–4.57a 14 3.61a 1.97–5.75a
Abbreviations are: O, observed cases; CI, confidence interval.
a 95% CI does not include 1.00
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Table 4. SIR for kidney cancer by sibling’s cancer
Brothers Sisters Both
Cancer site in sib O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 3 0.88 0.17–2.16 2 0.92 0.09–2.63 5 0.90 0.28–1.85
Stomach 5 1.72 0.54–3.56 2 1.15 0.11–3.29 7 1.50 0.60–2.83
Colon 3 0.42 0.08–1.02 5 1.13 0.36–2.34 8 0.69 0.29–1.25
Rectum 6 1.41 0.51–2.76 5 1.83 0.58–3.79 11 1.57 0.78–2.64
Liver 3 1.35 0.26–3.32 1 0.72 0.00–2.83 4 1.11 0.29–2.46
Pancreas 4 1.75 0.45–3.88 3 2.10 0.40–5.14 7 1.88 0.75–3.53
Lung 11 1.33 0.66–2.23 4 0.79 0.21–1.75 15 1.12 0.63–1.76
Breast 36 1.06 0.74–1.44 18 0.89 0.53–1.35 54 1.00 0.75–1.28
Cervix 4 0.66 0.17–1.47 7 1.92 0.76–3.61 11 1.14 0.56–1.91
Endometrium 4 0.72 0.19–1.61 3 0.95 0.18–2.33 7 0.81 0.32–1.51
Ovary 9 1.45 0.66–2.54 8 2.36a 0.01–4.28a 17 1.77a 1.03–2.71a
Prostrate 4 0.69 0.18–1.54 5 1.46 0.46–3.02 9 0.98 0.44–1.73
Kidney 18 4.34a 1.81–9.29a 14 5.34a 2.06–12.02a 32 4.72a 2.28–9.20a
Renal parenchyma 16 4.53a 1.83–9.93a 12 5.54a 2.02–12.90a 28 4.91a 2.31–9.76a
Renal pelvis 2 7.56 0.50–30.66 1 4.09 0.00–22.68 3 5.90 0.79–20.44
Unspecified 0 1 4.64 0.00–25.74 1 1.73 0.00–9.60
Urinary bladder 6 1.18 0.43–2.32 4 1.24 0.32–2.76 10 1.21 0.57–2.07
Melanoma 16 1.56 0.89–2.41 9 1.43 0.65–2.52 25 1.51 0.98–2.16
Skin 6 2.27 0.82–4.45 3 1.85 0.35–4.52 9 2.11 0.96–3.71
Nervous system 13 1.43 0.76–2.32 5 0.89 0.28–1.85 18 1.23 0.73–1.86
Endocrine glands 12 2.37a 1.22–3.90a 1 0.34 0.00–1.33 13 1.62 0.86–2.63
Non-Hodgkin 9 1.52 0.69–2.67 1 0.27 0.00–1.07 10 1.04 0.50–1.78
Leukemia 4 0.96 0.25–2.14 3 1.11 0.21–2.73 7 1.02 0.41–1.92
Any cancer 173 1.19 1.02–1.38 111 1.26 1.04–1.51 284 1.22 1.08–1.36
Abbreviations are: O, observed cases; CI, confidence interval.
a 95% CI does not include 1.00
Table 5. SIR for second primary cancer after kidney cancer
Follow-up interval
1 year 1–10 years 10 years All
Second cancer O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 1 0.38 0.00–1.49 12 0.70 0.36–1.15 3 0.43 0.08–1.06 16 0.60 0.34–0.93
Stomach 8 1.49 0.64–2.71 39 1.11 0.79–1.48 19 1.19 0.71–1.78 66 1.17 0.90–1.46
Colon 13 1.62 0.86–2.61 72 1.34 1.05–1.66 37 1.44c 1.02–1.95c 122 1.39c 1.16–1.65c
Rectum 2 0.41 0.04–1.18 33 1.03 0.71–1.41 14 0.97 0.53–1.55 49 0.96 0.71–1.24
Liver 9 2.68c 1.21–4.71c 23 1.02 0.64–1.47 15 1.38 0.77–2.16 47 1.27 0.94–1.67
Pancreas 7 2.05 0.81–3.85 39 1.71c 1.22–2.29c 20 1.93c 1.18–2.87c 66 1.81c 1.40–2.27c
Lung 17 1.91c 1.11–2.93c 70 1.21 0.94–1.50 36 1.52c 1.07–2.06c 123 1.36c 1.13–1.61c
Breast 10 1.14 0.54–1.96 68 1.10 0.85–1.37 45 1.63c 1.19–2.14c 123 1.25c 1.04–1.48c
Cervix 0 5 0.74 0.23–1.54 0 5 0.48 0.15–1.00
Endometrium 2 0.87 0.08–2.50 20 1.23 0.75–1.83 6 0.86 0.31–1.68 28 1.10 0.73–1.54
Ovary 3 1.65 0.31–4.06 14 1.09 0.59–1.74 5 0.92 0.29–1.90 22 1.09 0.68–1.60
Prostrate 55 2.86c 2.15–3.66c 197 1.61c 1.39–1.84c 85 1.50c 1.20–1.83c 337 1.70c 1.52–1.88c
Kidney 12 3.41c 1.76–5.62c 35 1.50c 1.05–2.04c 26 2.69c 1.76–3.83c 73 2.00c 1.57–2.49c
Urinary bladder 89 15.26c 12.25–18.59c 152 4.01c 3.40–4.67c 35 2.09c 1.46–2.84c 276 4.56c 4.04–5.12c
Melanoma 3 1.22 0.23–3.00 15 0.92 0.52–1.45 7 1.07 0.42–2.01 25 0.99 0.64–1.42
Skin 6 1.61 0.58–3.15 22 0.89 0.56–1.30 18 1.34 0.79–2.04 46 1.10 0.81–1.44
Nervous system 47 18.33c 13.46–23.94c 48 2.80c 2.07–3.65c 13 1.98c 1.05–3.21c 108 4.12c 3.38–4.93c
Hemangioblastomaa 2 83.00c 7.82–237.89c 3 18.99c 3.58–46.55c 0 5 21.19c 6.69–43.83c
Familial casesb 0 2 1667.91c 157.23–4780.43c 0 2 1205.69c 113.66–3455.67c
Other 45 17.72c 12.92–23.28c 45 2.65c 1.93–3.48c 13 2.00c 1.06–3.24c 103 3.96c 3.23–4.76c
Endocrine glands 44 29.64c 21.53–39.05c 22 2.17c 1.36–3.17c 17 4.06c 2.36–6.22c 83 5.25c 4.18–6.44c
Non-Hodgkin 13 4.28c 2.27–6.92c 36 1.78c 1.25–2.41c 11 1.22 0.61–2.05 60 1.86c 1.42–2.36c
Leukemia 19 6.56c 3.94–9.84c 35 1.82c 1.27–2.48c 21 2.46c 1.52–3.63c 75 2.45c 1.93–3.03c
Any cancer 396 3.77c 3.40–4.15c 1031 1.48c 1.39–1.57c 473 1.51c 1.38–1.65c 1900 1.70c 1.63–1.78c
Abbreviations are: O, observed cases; CI, confidence interval.
a Hemangioblastoma was defined as benign tumor of the central nervous system
b Familial cases: first-degree relatives (parents, siblings, offspring) whoever with kidney cancer
c 95% CI does not include 1.00
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with a SIR of 4.72 (2.28–9.20) was significantly higher the present epidemiological data do not allow their iden-
tification, probably because of their rarity and the lackwhen compared to offspring risk for kidney cancer. One
possible reason for higher sibling risks could be the of established associated malignancies. Brain cancer is
a manifestation in tuberous sclerosis, but we found noyounger age distribution. However, a statistically sig-
nificant ratio of sibling risk to offspring risk of 2.43 (1.51 association between kidney and brain cancer in any age
group.to 3.90) was shown when the age of parents in our analy-
sis was limited to 66 years (the same as for offspring). The Second primary cancers may be a result of the same
genetic factors as the first cancers and therefore havepopulation-attributable proportion by parental cancer
(using familial SIR data from Table 2) was 0.78% and been of interest in genetic epidemiology. On the other
hand, second primary cancers also may arise due to thethe attributable proportion by sibling’s cancer was 0.77%
(using familial SIR values from Table 4). These values treatment of the first cancer, or they may be diagnosed
earlier because of the medical follow-up of the first can-are somewhat lower compared to estimates from case-
control studies that suggest that up to 4% of kidney cer. Moreover, the second primary cancer may be a re-
currence of the first cancer. To be able to distinguishcarcinomas may be hereditary [1, 11].
The genetic interpretation of the familial risks is that between these factors, we subdivided the follow-up pe-
riod (Table 5). The increase in risk of the second cancersdominant effects are reflected in offspring risks (and in
sibling risks when a parent is affected) whereas recessive was largest during the first year of follow-up and most
likely is due to the intensive medical surveillance aftereffects are signaled by elevated sibling risks with no
parent affected. The risk to offspring from an affected the first diagnosis. It is probable that urologists treating
patients for kidney cancer found an increase in anotherparent was of moderate magnitude in our study and can
be at least partly explained by a dominant susceptibility urologic malignancy, for example, prostate cancer or uri-
nary bladder cancer.due to the VHL gene. Although a high ratio of sibling
risk to offspring risk is consistent with an involvement Treatment-related effects in solid tumors would be
expected to manifest after about a decade from the diag-of recessive susceptibility, a high sibling risk of kidney
cancer in this study could be explained partly by a shared nosis of the first cancer [34–36]. However, there was no
significant increase in risks 11 to 37 years after the firstchildhood environment. Still, little is known about the
relative importance of genes and environment in familial diagnosis, compared to 1 to 10 years for most second
cancers, excluding any large effects by treatment. Indeed,clustering of cancer, and in twin studies the effect of a
shared environment is a minor cause of cancer [6]. because the primary treatment modality for kidney can-
cer is surgery, the basis for the association between kid-Our analysis revealed a few discordant sites that asso-
ciated with familial kidney cancer. A VHL related tumor ney cancer and second cancers is unlikely to be treatment
related, but possibly due to common etiologic factors,site that associated with an increased kidney cancer risk
between the two generations was hemangioblastoma of either environmental or genetic.
Higher SIRs were seen in the 1 to 10 year intervalcentral nervous system (Table 3). VHL related cancers
that associated with kidney cancer among siblings were compared to 11 to 37 year interval for cancers at urinary
bladder (4.01) and nervous system (2.80). As an increasethose of endocrine glands with SIR of 2.37 (1.22 to 3.90)
in males and pancreas with SIR of 3.53 (only for age of of risk for second cancer in the 1 to 10 year interval is
likely to signal inherited or acquired susceptibility toonset 50 years). We also showed an association of
kidney cancer with ovaries, colon and urinary bladder cancer, it would be interesting to compare the patterns
of multiple cancers in familial and sporadic cancer. How-cancers that were most probably due to hereditary non-
polyposis colorectal cancer (HNPCC) syndrome [12, 32, ever, only the nervous system had more than two familial
cases of tumors (Table 5). The highest risk of second33]. Ovaries were associated with sibling risk for kidney
cancer resulting in a SIR of 1.77 (1.03 to 2.71). Colon or primary tumor was seen for hemangioblastoma, a benign
tumor of central nervous system, with a SIR of 18.99.urinary bladder cancer in parent in families with siblings
affected with kidney cancer resulted in high familial risks: Among three cases in the 1 to 10 year interval, there
were two cases of familial hemangioblastoma followingfour cases of parental colon cancer in SIR of 17.57 (3.23
to 55.15) and four cases of parental bladder cancer in kidney cancer, giving a SIR value of 1668 (157 to 4780).
The association between hemangioblastoma and kidneySIR of 32.35 (5.95 to 101.58). Multiple comparisons by
cancer site in parent/sibling could possibly result in sig- cancer in Table 5 (and also in Table 3) is likely to cover
all VHL kidney cancer cases.nificant findings on the basis of chance. However, biolog-
ical plausibility and previous epidemiological and molec- While familial risks associated with the VHL syn-
drome were high according to our analysis, they canular genetic data support the associations found in our
study. explain only a small proportion of kidney cancers since
it is a rare syndrome. The high ratio of sibling risk toEven though other renal cancer syndromes have been
identified, as discussed in the introductory paragraphs, offspring risk in kidney cancer may be indicative of a
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